December 2023

  • All
  • --
  • ---
  • -2022
  • 2022-2
  • 2022-2-2-2
  • 2022-deltia-tipoy
  • 2022-deltia-tipoy-2-2
  • 2022-deltia-tipoy-2-2-2-2
  • 2023-deltia-typou
  • 2023-deltia-typou-2-2
  • 2024
  • 257-2
  • 257-2-2-2
  • 266-2
  • Announcements
  • Consolidated Financial Results
  • deltia-tipoy
  • deltia-tipoy-2-2
  • deltia-tipoy-2-2-2-2
  • Distribution of Divident
  • Events
  • FAQ
  • General Meetings and Corporate Actions
  • Insiders Transactions Disclosures
  • Invitations
  • invitations-2
  • Presentations
  • Press Kits
  • Press Releases
  • Regulated Information
  • Results 2024
  • Share Capital Increase
  • Uncategorized

Paiania, 11 December 2023 – Lavipharm S.A. announced today, in accordance with Regulation 596/2014/EU, that it has entered into an Asset Purhase Agreement with Sanofi for the acquisition of the pharmaceutical product Flagyl® for the Greek market. Commercialization of the product by Lavipharm is expected to...

Paiania, 11 December 2023 – Lavipharm S.A. announced today, in accordance with Regulation 596/2014/EU, that it has entered into an Asset Purhase Agreement with Sanofi for the acquisition of the pharmaceutical product Flagyl® for the Greek market. Commercialization of the product by Lavipharm is expected to...

Paiania, 6 December 2023 - Marking a remarkable year since its successful Share Capital Increase, Lavipharm, the sole Greek pharmaceutical company listed on the Athens Stock Exchange, proudly commenced today’s trading session. At this special event held at the Athens Exchange, Telemaque Lavidas, Executive Board...

Paiania, 1 December 2023 - Lavipharm S.A. announces, in accordance with Regulation 596/2014/EU, the signing of an asset purchase agreement with Boehringer Ingelheim International GmbH for the acquisition of two analgesic pharmaceutical products, Lonarid N® and Lonalgal®, for the markets of Greece and Cyprus with...

Paiania, 1 December 2023 - Lavipharm S.A. announces, in accordance with Regulation 596/2014/EU, the signing of an asset purchase agreement with Boehringer Ingelheim International GmbH for the acquisition of two analgesic pharmaceutical products, Lonarid N® and Lonalgal®, for the markets of Greece and Cyprus with...